Radiotherapy devices are used in cancer treatment by using high doses of radiation to kill cancer cells and shrink tumors. The main product type of radiotherapy devices is external beam radiation therapy devices, linear accelerator devices, and proton therapy devices. A medical linear accelerator (LINAC) is a radiotherapy device that is generally utilized for external beam radiation treatments for patients with cancer. It supplies high-energy x-rays or electrons to the region of the patient's tumor. The applications are skin cancer, breast cancer, prostate cancer, cervical cancer, lung cancer, and others. These are used in hospitals, ambulatory surgical centers, and oncological treatment centers. The radiotherapy devices market research report is one of a series of new reports from The Business Research Company that provides radiotherapy devices market statistics, including radiotherapy devices industry global market size, regional shares, competitors with a radiotherapy devices market share, detailed radiotherapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the radiotherapy devices industry. This radiotherapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global radiotherapy devices market grew from $5.21 billion in 2022 to $5.69 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The radiotherapy devices market is expected to grow from $8.07 billion in 2027 at a CAGR of 9.1%. Technological advancement is anticipated to drive the demand for the radiotherapy devices market. The advancement in technology is helping to develop low-cost, more effective and efficient, and user-friendly products with precise and improved radiation doses for increased performance in targeting tumors. The advancement from 2D radiotherapy devices to 3D with real-time imaging enabled high conformity of radiation to improve tumor control. For instance, in June 2020, Accuray Incorporated, a US-based radiation oncology company launched CyberKnife S7 System, a radiotherapy device combining advanced precision, real-time artificial intelligence, and speed motion tracking and synchronization treatment delivery for stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatments. Therefore, the launch of advanced devices is likely to propel the revenues for the radiotherapy devices market shortly. The high cost of radiotherapy is projected to limit the growth of the radiotherapy devices market as it uses complex machines and involves the services of skilled health care providers. The specific expense of radiation treatment relies upon the expense of medicinal services such as place of patient residence, type of radiation treatment, and the number of medicines required. For example, Proton Therapy is a high-cost therapy that is usually performed in metropolitical cities or at major academic centers. The treatment duration is eight weeks, which leads to huge expenditure on treatment and relocation. According to the report of the National Cancer Institutes, approximately $150.8 billion were spent nationally for cancer care in 2018 in America. The high costs of cancer treatment are especially difficult to overcome among the poor or the uninsured or underinsured population. Therefore, the high cost associated with radiotherapy procedures is expected to restrain the growth of the market. Artificial Intelligence (AI) is a leading trend in the radiotherapy devices market and is gaining significant popularity in the market. The incorporation of AI innovation in disease care is expected to improve the exactness and speed of analysis, help clinical dynamics, and lead to better results. For instance, in October 2022, HCG cancer hospital launched AI-based radiation treatment technology for efficient radiotherapy. The traditional treatment arranging process takes days to make an improved radiation treatment conveyance plan; however, the new AI advancements are helping to speed up this procedure. AI is also expected to include deep learning applications in treatment planning, clinical decision support, automated image-guided adaptive radiation therapy, and genomic/radio-biologic data mining, thus supporting the growth of the market. In August 2020, Siemens Healthineers, a Germany-based medical technology company, announced its decision to acquire Varian Medical Systems Inc., for $16.4 billion. The deal is expected to expand Siemens Healthineer's definitive objective of overarching and comprehensive oncology portfolio, including Varian's linear accelerators, radiosurgery devices, and proton therapy suites to Siemens' imaging hardware, laboratory diagnostics, and hospital consulting services. Varian Medical Systems Inc. is a US-based radiation oncology treatments and software company. Major players in the radiotherapy devices market are Varian Medical Systems, Elekta AB, Accuray Inc., C.R.Bard Inc., IBA Ion Beam Applications SA, Koninklijke Philips N.V, Siemens AG, Eckert & Ziegler Bebig, IsoRay Inc., and GE Healthcare. North America was the largest region in the radiotherapy devices market in 2022. Asia-Pacific was the second largest region in the global radiotherapy devices market report. The regions covered in the global radiotherapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the radiotherapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The radiotherapy devices market consists of sales of external beam radiation therapy devices, linear accelerator devices, and proton therapy devices that are used for radiotherapy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global radiotherapy devices market is segmented - 1) By Product Type: External Beam Radiation Therapy Devices, Linear Accelerator Devices, Proton Therapy Devices 2) By Application: Skin Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Lung Cancer, Other Applications 3) By End Users: Hospitals, Ambulatory Surgical Centers, Oncological Treatment Centers

Interventional radiology is a field of radiology that uses medical imaging to guide minimally invasive surgical procedures for diagnosis and treatment. The main types of products in the interventional radiology market are MRI, ultrasound imaging, CT scanners, angiography systems, fluoroscopy systems, biopsy devices, and others. MRI interventional radiology devices scan produce detailed images of the organs and tissues in the body. The different procedures include angioplasty, angiography, biopsy and drainage, embolization, thrombolysis, vertebroplasty, nephrostomy, and others and are used in cardiology, urology and nephrology, oncology, gastroenterology, and others. The interventional radiology market research report is one of a series of new reports from The Business Research Company that provides interventional radiology market statistics, including interventional radiology industry global market size, regional shares, competitors with a interventional radiology market share, detailed interventional radiology market segments, market trends and opportunities, and any further data you may need to thrive in the interventional radiology industry. This interventional radiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global interventional radiology market size grew from $20.68 billion in 2022 to $22.57 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interventional radiology market size is expected to grow to $31.77 billion in 2027 at a CAGR of 8.9%. The increase in prevalence of cancer is expected to drive the growth of the interventional radiology market in the coming years. Cancer is a global health problem and is the second leading cause of death in the United States. Interventional radiology uses a variety of techniques such as ablation, embolization, and irreversible electroporation (IRE) to treat cancer and cardiovascular disorders. For instance, according to the American Cancer Society, there were 1,806,590 new cancer cases and 606,520 cancer deaths in 2020 in the USA. New cases of leukemia, lymphoma, and myeloma are expected to account for 9.9% of the estimated 178,520 new cases diagnosed in the USA in 2020 and in approximately every 3 minutes one person in the US is diagnosed with blood cancer. Hence, the increasing prevalence of cancer drives the growth of the interventional radiology market. Artificial Intelligence is a key trend gaining popularity in the interventional radiology market. Companies operating in the interventional radiology sector continuously focus on introducing new technologies to survive in the interventional radiology market. For instance, in September 2012, GE Healthcare, a US-based manufacturer and distributor of diagnostic imaging, launched AI-powered Cath lab - Optima IGS 320in India. It uses GE's AutoRight technology, which automates image and dose parameter optimization in real-time using AI so that doctors may concentrate their attention and clinical experience on patients. The Optima IGS 320's next-generation interventional imaging software offers clinical adaptability to more precisely direct complex non-invasive procedures. By using AutoRight to automate the often difficult process, interventionists are given less work to do and may pay more attention to the process. In August 2020, Seimens Healthineers, a Germany-based medical device manufacturer specializing in medical imaging, laboratory diagnostics, point of care diagnostics, and other segments acquired Varian for $16.4 billion. With this acquisition, Seimens plans to expand its cancer devices portfolio used for screening and treating different cancers. Varian is a UK-based medical technology company that provides products for radio-oncology treatments. Major players in the interventional radiology market are Carestream Health, Siemens AG, Koninklijke Philips N.V., General Electric Company, Hitachi Medical Corporation, Canon Medical Systems Corporation, Toshiba Medical Systems, Medtronic plc, Shimadzu Corporation, Fujifilm Holdings Corp., Hologic Inc., Agfa-Gevert N.V., Esaote S.P.A., and Samsung Medison. North America was the largest region in the interventional radiology market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interventional radiology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the interventional radiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The interventional radiology market consists of sales of atherectomy systems, cancer therapies, and balloon catheters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global interventional radiology market is segmented - 1) By Product: MRI, Ultrasound Imaging, CT Scanners, Angiography Systems, Fluoroscopy Systems, Biopsy Devices, Other Products 2) By Procedure: Angioplasty, Angiography, Biopsy And Drainage, Embolization, Thrombolysis, Vertebroplasty, Nephrostomy, Other Procedures 3) By Application: Oncology, Cardiology, Urology And Nephrology, Gastroenterology, Other Applications

Radiology as a service refers to rendering professional and technical services for radiation oncology, radioisotope services, medical imaging, and so on to allow providers to provide patients with the best possible diagnoses at much lower costs. The main types of radiology as a service are teleradiology, cloud-based imaging services, consulting services, and technology management services. Teleradiology is used to send radiological pictures to other institutions for reports from licensed radiologists. Teleradiology refers to a type of telemedicine in which radiological pictures are sent to other facilities via telecommunications for analysis by competent radiologists. This approach is used to send reports from imaging tests such as X-rays. MRI scan. The different technologies include computed radiology and direct digital radiology, which are used by various end-users such as hospitals, diagnostic imaging centers, radiology clinics, physician offices, and nursing homes. The radiology as a service market research report is one of a series of new reports from The Business Research Company that provides radiology as a service market statistics, including radiology as a service industry global market size, regional shares, competitors with radiology as a service market share, detailed radiology as a service market segments, market trends and opportunities, and any further data you may need to thrive in the radiology as a service industry. This anomaly detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global radiology as a service market size grew from $1.33 billion in 2022 to $1.63 billion in 2023 at a compound annual growth rate (CAGR) of 23.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The radiology as a service market size is expected to grow to $3.49 billion in 2027 at a CAGR of 20.9%. An increase in the number of cancer cases globally is expected to propel the growth of radiology as a service market going forward. Cancer is a condition when the body's cells grow out of control and spread to other bodily regions. Medical imaging technology has transformed healthcare by enabling earlier cancer detection and better patient outcomes. Hence, the rise in the number of cancer cases would result in a demand for radiology imaging services, which is expected to propel the growth of radiology as a service. For instance, according to the National Cancer Institute, a US-based government agency for cancer research and training, the global number of new cancer cases per year is predicted to reach 29.5 million, with 16.4 million cancer-related deaths by 2040. Therefore, the increasing number of cancer cases is driving the market growth of radiology as a service market. Technological advancements are the key trends gaining popularity in the radiology-as-a-service market. Major companies operating in the radiology-as-a-service sector are focused on introducing new technologies to sustain their position in the market. For example, in January 2021, Nanox, an Israel-based medical imaging technology company, and USARAD, a US-based teleradiology company, introduced an advanced radiology diagnostics service that combines over 300 expert radiologists with artificial intelligence decision support solutions to support medical diagnostics. In July 2021, RamSoft, a Canada-based medical imaging services company, acquired Meddiff Technologies for an undisclosed amount. This deal would speed RamSoft's product development by integrating the product lines and expertise of Meddiff and RamSoftand also help RamSoft increase its customer base in Asia, the Middle East, and the United Kingdom. Meddiff is an India-based medical imaging solutions company that provides teleradiology services. Major players in the radiology as a service market are Philips Healthcare, GE Healthcare, Nano-X Imaging Ltd., USARAD Holdings Inc., Virtual Radiologic, Onrad Inc., RamSoft Inc., Telediagnostic Solutions Private Limited, Teleradiology Solutions, National Diagnostic Imaging, Real Radiology LLC, Telemedicine Clinic Ltd., Vesta Teleradiology, Ambra Health, Teleconsult Holding B.V, and Medica Group PLC. North America was the largest region in the radiology as a service market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radiology as a service market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the radiology as a service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The radiology as a service market includes revenues earned by entities by radiation oncology, radioisotope services, medical imaging, and so on. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global radiology as a service market is segmented - 1) By Service Type: Teleradiology, Cloud-based Imaging IT Services, Consulting Services, Technology Management Services 2) By Technology: Computed Radiology, Direct Digital Radiology 3) By End-User: Hospitals, Diagnostic Imaging Centers, Radiology Clinics, Physician Offices, Nursing Homes

Radiopharmaceuticals refer to a medication used to treat or diagnose diseases, including cancer, that contains a radioactive material. Likewise known as radioactive medication. These are the procedures used to identify certain illnesses or detect medical issues. The patient may receive them in a number of different ways. They could be injected, injected orally, or injected into the eye or bladder, for instance. The main types of radiopharmaceuticals are diagnostic, therapeutic, and others. The delivery of radioactive atoms to tumor-associated targets is referred to as radiopharmaceutical therapeutic. The various applications include oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and others that are used by hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and others. The radiopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceuticals market statistics, including radiopharmaceuticals industry global market size, regional shares, competitors with a radiopharmaceuticals market share, detailed radiopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceuticals industry. This radiopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global radiopharmaceuticals market grew from $5.9 billion in 2022 to $6.17 billion in 2023 at a compound annual growth rate (CAGR) of 4.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The radiopharmaceuticals market is expected to grow from $8.25 billion in 2027 at a CAGR of 7.5%. The increasing prevalence of cancer and cardiovascular diseases is projected to drive the demand for the radiopharmaceuticals market. Radiopharmaceuticals are emerging as a safe and effective therapeutic option over conventional medicines. Radiopharmaceuticals provide an upper hand to radiologists to treat cancer and cardiovascular diseases due to their benefits such as targeted therapy. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. According to the International Agency for Research on Cancer (IARC), by 2040, the global burden is projected to increase to 27.5 million active cancer incidents and 16.3 million cancer deaths primarily due to population growth and aging. About 70% of deaths from cancer occur in low- and middle-income countries. Thus, the rising cases of cancer and cardiovascular diseases are expected to surge the demand for radiopharmaceuticals for the treatment of these diseases. The high cost of radiopharmaceuticals is anticipated to limit the growth of the market. High costs and short half-life of radiopharmaceuticals are reducing their implementation in hospitals and clinics. The development cost of radiopharmaceuticals is very high compared to that of therapeutic drugs and also undergoes a very lengthy and expensive regulatory process. For instance, the cost of diagnostic radiopharmaceuticals development is $100 to $200 million for 8-10 years in comparison with the cost of pharmaceuticals, which ranges between $600 million to $1.2 billion for 10-12 years. Therefore, the high cost of radiopharmaceuticals is likely to act as a major restraint on market growth. Research collaborations and partnerships are gaining significant popularity in the radiopharmaceuticals market over recent years. Major companies operating in the radiopharmaceuticals market are collaborating with other industry players to conduct R&D activities to expand their business. For instance, in March 2020, Debiopharm, a Switzerland-based biopharmaceutical company, signed a research agreement with 3B Pharmaceuticals (3BP), a Germany-based biotechnology firm, to develop the Debio 0228 radioligand program, targeting CAIX (Carbonic Anhydrase 9) enzyme to fight the progression of cancer. Many companies are adopting various strategic initiatives, such as opening a new manufacturing facility and expanding plant capacity, which is gaining significant popularity in the radiopharmaceuticals market. For instance, ITM Isotopen Technologien Munchen AG (ITM) announced the launch of its new manufacturing facility in the Munich area to increase the production capacity of high-purity (n.c.a.) Lutetium-177 and no-carrier-added (n.c.a.) Lutetium-177 containing radiopharmaceuticals. Lutetium-177 is popular under the brand EndolucinBeta and is an innovative isotope used in cancer therapy. This is the company’s step towards meeting the high demand for quality medical isotopes for precision oncology worldwide. In June 2021, Curium, a France-based nuclear medicine solution provider, acquired IASON for an undisclosed amount. Through this acquisition, Curium is expected to increase its footprint in Europe for its extensive selection of life-saving diagnostic techniques. This acquisition expands Curium's geographic reach, allowing it to reach clients and patients throughout Austria and Central Europe with its wide range of medications and future pipeline of novel agents. IASON is an Austria-based expert in radiopharmaceutical development, manufacturing, and distribution for use in positron-emission tomography (PET). Major players in the radiopharmaceuticals market are Siemens Healthcare Private Limited, Bayer, GE Healthcare, Novartis AG, Cardinal Health, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Nordion Inc. (A subsidiary of Sterigenics International), Mallinckrodt PLC., Curium, Eckert & Ziegler, Eli Lilly, Eckert & Ziegler, IBA Group, Merck & Co. Inc., Philips Healthcare, Fujifilm Holding Corporation, Areva Pharma, Navidea Biopharmaceuticals Inc., Actinium Pharmaceuticals Inc., Global Medical Solutions LTD., and Shine Medical Technologies. North America was the largest region in the global radiopharmaceuticals market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global radiopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the radiopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The radiopharmaceuticals market consists of sales of technetium disofenin, technetium lidofenin, and technetium mebrofenin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global radiopharmaceuticals market is segmented - 1) By Type: Diagnostic, Therapeutic, Other Types 2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinnology, Neurology, Nephrology, Other Applications 3) By End User: Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes, and Other End Users

RFID tags are small devices with a chip and an antenna that may be used to wirelessly identify the objects they are attached to by using an RFID reader. RFID tags transmit their identification, track, and communicate information to adjacent readers through radio waves, and can store a variety of data ranging from a single serial number to multiple pages of information. It uses that use hardware and software technologies that allow users to receive, store, and transmit data through radio frequency waves. The main types of radio-frequency identification (RFID) tags are active RFID and passive RFID. The active RFID tags are battery-powered sensor tags that connect to various access points throughout an area (such as a building) and transfer data to the cloud. Active RFID is frequently used in real-time location tracking. The different materials include plastic, paper, glass, others and operate in various frequencies such as low frequency, high frequency, ultra-high frequency. It is used in several applications including agriculture, retail and wholesale, healthcare, BFSI, transpiration and logistics, education, and others. The radio-frequency identification (RFID) tags market research report is one of a series of new reports from The Business Research Company that provides radio-frequency identification (RFID) tags market statistics, including radio-frequency identification (RFID) tags industry global market size, regional shares, competitors with a radio-frequency identification (RFID) tags market share, detailed radio-frequency identification (RFID) tags market segments, market trends and opportunities, and any further data you may need to thrive in the radio-frequency identification (RFID) tags industry. This radio-frequency identification (RFID) tags market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global radiofrequency identification (RFID) tags market size grew from $10.3 billion in 2022 to $11.46 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The radiofrequency identification (RFID) tags market size is expected to grow to $15.72 billion in 2027 at a CAGR of 8.2%. The rising e-commerce and online retail sales are expected to propel the growth of the RFID tags market in the forecast period. E-commerce (electronic commerce) is the buying and marketing of goods and services over a computer network, most often the internet, as well as the exchange of payments and information. RFID technology gives e-commerce organizations a better picture of the supply chain, allowing them to find what they need to fulfill a customer's request. For instance, according to the United Nations Conference on Trade and Development (UNCTAD) report, a Switzerland-based intergovernmental organization for trade and development, in 2020, the worldwide share of sales of online retail increased from 16% in 2019 to 19% in 2020. Therefore, the rising e-commerce and online retail sales drive the growth of the RFID tags market. RFID companies are increasingly implementing advanced technologies such as IoT and Big Data which is a growing trend in the market. With the help of IoT, RFID tags can connect objects into a network and make them create and send data. It assists in the real-time monitoring of tagged objects and the creation of a system of connected devices that broadcast information about their position, conditions, and quantities in real-time. For instance, in February 2020, Omni-ID, a US-based company operating in passive industrial radio frequency identification (RFID) tags, introduced a new range of Bluetooth Low Energy (BLE) and Long Range (LoRa) enabled IoT devices that utilize a comprehensive set of sensors with the ability to transmit situational and status data using Radiofrequency Identification (RFID) tags to enhance asset Management & Logistics process in an organization. In May 2022, HID Global, a US-based manufacturer of secure identity products acquired Vizinex RFID for an undisclosed amount. Through this acquisition, HID Global aims to expand its RFID tag portfolio in healthcare/medical, manufacturing, oil & gas, data centers, and others. Vizinex RFID is a US-based company operating in RFID tags. Major players in the radiofrequency identification (RFID) tags market are Avery Dennison, Zebra Technologies, Honeywell, NXP Semiconductors, Impinj Inc., Invengo Technology Pte. Ltd., ams AG, Atmel Corp, Alien Technology, Smartrac N.V., GAO RFID Inc., The Tag Factory, and MOJIX. North America was the largest region in the radio-frequency identification (RFID) tags market in 2022. The regions covered in the radiofrequency identification (RFID) tags report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the radiofrequency identification (RFID) tags market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The radiofrequency identification (RFID) tags market consists of sales scanning antenna, a transceiver and a transponder.Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global radiofrequency identification rfid tags market is segmented - 1) By Tag Type: Active RFID, Passive RFID 2) By Material: Plastic, Paper, Glass, Other Materials 3) By Frequency: Low Frequency, High Frequency, Ultra High Frequency 4) By Application: Agriculture, Retail And Wholesale, Healthcare, BFSI, Transpiration And Logistics, Education, Other Applications

A veterinary stereotactic radiosurgery system refers to a form of external radiation therapy that positions the patient precisely while administering a single, high dosage of radiation to a tumour. The main types of veterinary stereotactic radiosurgery systems are microsurgical instrumentation, optical or viewing instruments, and other products. Microsurgical instrumentation refers to surgical tools that are held in the hand and are made especially for microsurgical and delicate procedures, holding fragile tissues, tendons, and blood vessels. The various modality involved are gamma knife, linear accelerator, particle beam radiation therapy, and cyber knife that are used for canine, feline, and other applications. The different end users include hospitals, contract research organizations (CROs), and others. The veterinary stereotactic radiosurgery system market research report is one of a series of new reports from The Business Research Company that provides veterinary stereotactic radiosurgery system market statistics, including veterinary stereotactic radiosurgery system industry global market size, regional shares, competitors with veterinary stereotactic radiosurgery system market share, detailed veterinary stereotactic radiosurgery system market segments, market trends, and opportunities, and any further data you may need to thrive in the veterinary stereotactic radiosurgery system industry. This veterinary stereotactic radiosurgery system market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global veterinary stereotactic radiosurgery system market size grew from $2.35 billion in 2022 to $2.69 billion in 2023 at a compound annual growth rate (CAGR) of 14.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The veterinary stereotactic radiosurgery system market size is expected to grow to $4.44 billion in 2027 at a CAGR of 13.3%. The rise in the pet population is expected to propel the growth of the veterinary stereotactic radiosurgery system market going forward. A pet refers to an animal that keep in the house for enjoyment and company. The veterinary stereotactic radiosurgery system aids in the treatment of tumors in pets with a variety of head sizes and shapes. For instance, according to the survey, named 'The Market for Pet Owners' of over 2,000 pet owners in the USA in October 2020, conducted by The American Veterinary Medical Association, a US-based not-for-profit association representing veterinarians in the US, 45% of households had dogs in 2020. In 2019, between 83.7 million and 88.9 million dogs were reported to be kept as pets, and 26% of households had cats. Therefore, the rise in the pet population is driving the growth of the veterinary stereotactic radiosurgery system market. Technological advancements are a key trend gaining popularity in the veterinary stereotactic radiosurgery system market. Major players operating in the market are developing advanced technologies to sustain their position in the veterinary stereotactic radiosurgery system market. For instance, in June 2020, Accuray Incorporated, a US-based manufacturer of radiotherapy systems, launched the CyberKnife S7 system, the latest generation of the company's CyberKnife radiation therapy platform. Stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments are administered by the robotic radiation therapy system in a 15-minute time frame. It tackles neurological diseases as well as benign and malignant cancers throughout the body. In order to tailor radiation administration in real-time to the patient and/or tumor movement, S7 leverages Accuray's Synchrony motion-synchronization technology. The system's unique robotic architecture enables the delivery of radiation from possibly thousands of different angles. In April 2021, Siemens Healthineers, a Germany-based healthcare company, acquired Varian Medical Systems for an undisclosed amount. This acquisition increases Siemen’s influence on the world of healthcare and solidifies its position as a reliable partner for clients and patients throughout the full cancer care continuum as well as for many of the most dangerous illnesses. Varian Medical Systems is a UK-based healthcare company providing stereotactic radiosurgery systems for veterinary use. Major players in the veterinary stereotactic radiosurgery system market are PetCure Oncology, Elekta AB, Accuray, Varian Medical Systems, C. R. Bard Inc., Nanovi Radiotherapy A/S, and Ion Beam Applications SA. North America was the largest region in the veterinary stereotactic radiosurgery system market in 2022. The regions covered in the veterinary stereotactic radiosurgery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the veterinary stereotactic radiosurgery system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. A veterinary stereotactic radiosurgery system market includes revenues earned by entities by veterinary stereotactic radiosurgery system that are used in the treatment of cancers and other issues that affect the brain, neck, lungs, liver, spine, and other areas of the body of pets and animals. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary stereotactic radiosurgery system market is segmented - 1) By Product: Microsurgical Instrumentation, Optical or Viewing Instruments, Other Products 2) By Modality: Gamma Knife, Linear Accelerator, Particle Beam Radiation Therapy, Cyber Knife 3) By Application: Canine, Feline, Other Applications 4) By End User: Hospitals, Contract Research Organizations (CROs), Other End Users

Digital X-ray devices are digital sensors that are used to image the human body instead of traditional photographic films. These are used for instant diagnostic imaging. The main technologies of digital X-ray include direct radiography and computed radiography. Direct digital radiography (DDR) refers to direct digital registration of the image at the detector with no intermediate processing step required to obtain the digital signals as in computed radiography (CR). Digital X-ray devices are of various portability including handheld systems, portable x-ray systems, mobile x-ray systems, floor-to-ceiling mounted systems, ceiling-mounted systems, and fixed digital x-ray systems. Digital X-ray devices are used for applications such as general radiography, chest imaging applications, orthopedic applications, cardiovascular imaging, other general radiography applications, dental applications, mammography, cancer, and fluoroscopy. These are used by end-users including hospitals, diagnostic centers, and dental care centers. The digital X-ray market research report is one of a series of new reports from The Business Research Company that provides digital X-ray market statistics, including digital X-ray industry global market size, regional shares, competitors with a digital X-ray market share, detailed digital X-ray market segments, market trends and opportunities, and any further data you may need to thrive in the digital X-ray industry. This digital X-ray market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global digital x-ray devices market size grew from $10 billion in 2022 to $10.87 billion in 2023 at a compound annual growth rate (CAGR) of 8.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The digital x-ray devices market size is expected to grow to $15.45 billion in 2027 at a CAGR of 9.2%. The rising number of road accident cases is expected to propel the growth of the digital X-ray devices market over the coming years. A road accident is defined as the patients following a motor vehicle crash meeting Vittel criteria for the severity of the trauma, which opens up new demand for digital X-ray devices. For instance, according to the US federal government, road fatalities spiked in the first half of 2021, the largest increase ever recorded in its reporting system’s history during a six-month period. More than 20,000 people died in motor vehicle crashes on U.S. roads, a nearly 20% increase from the same period in 2020. Therefore, a rising number of road accidents cases drives the digital X-ray devices market. Technological advancements are a key trend gaining popularity in the digital X-ray devices market. Integration of AI provides an opportunity for use of digital X-ray devices in various applications. Artificial intelligence is used to engineer digital X-ray devices to detect coefficients and reduce diagnostic errors. For instance, in January 2020 Nanox, an innovative medical imaging technology company, developed a cloud-based software that will be designed to provide an end-to-end medical imaging service including, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing and reporting that help the digital X-ray devices market grow worldwide. In April 2021, Siemens Healthineers, a German medical device company, acquired Varian for an undisclosed amount. Through this acquisition, both the firms aim at securing a position in the cancer care and healthcare system. Moreover, they're building a strong and reliable partner capable of assisting clients and patients throughout the cancer care continuum and across all key therapeutic routes. Varian is a UK-based x-ray devices manufacturing company. Major players in the digital x-ray devices market are Siemens Healthineers, Koninklijke Philips N.V., GE Healthcare, Canon, Inc., Carestream Health, FUJIFILM Holdings Corporation, Shimadzu Corporation, Hologic Inc., Samsung Medison, Konica Minolta, Hitachi Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Varex Imaging Corporation, MinXray, Inc., ACTEON, Agfa-Gevaert Group. North America was the largest region in the digital X-ray devices market in 2022 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the digital X-ray devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digital x-ray devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The digital x-ray devices market consists of the sales of intraoral x-ray sensors, digital panoramic x-rays, dental cone beam systems, and phosphor plate x-ray systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digital x ray devices market is segmented - 1) By Technology: Direct Radiography, Computed Radiography 2) By Portability: Handheld Systems, Portable X-Ray Systems, Mobile X-Ray Systems, Floor-to-ceiling Mounted Systems, Ceiling Mounted Systems, Fixed Digital X-Ray Systems 3) By Application: General Radiography, Chest Imaging Applications, Orthopedic Applications, Cardiovascular Imaging, Other General Radiography Applications, Dental Applications, Mammography, Cancer, Fluoroscopy 4) By End Users: Hospitals, Diagnostic Centers, Dental Care Centers

Digital therapeutics (DTx) are the products that give evidence-based therapeutic treatments to patients through high-quality software applications in order to prevent, manage, or treat a medical ailment or disease. The main product types of digital therapeutics are devices and software. Digital therapeutics devices provide intervention to prevent, manage or treat a disease or medical disorder. This includes devices such as sensors used to track medication usage and location data. The different sales channels include business-to-business (B2B), business-to-consumer (B2C). Digital therapeutics are used in preventive applications and treatment or care-related applications. The digital therapeutics market research report is one of a series of new reports from The Business Research Company that provides digital therapeutics market statistics, including digital therapeutics industry global market size, regional shares, competitors with a digital therapeutics market share, detailed digital therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the digital therapeutics industry. This digital therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global digital therapeutics market size grew from $5.53 billion in 2022 to $6.93 billion in 2023 at a compound annual growth rate (CAGR) of 25.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The digital therapeutics market size is expected to grow to $17.19 billion in 2027 at a CAGR of 25.5%. The increase in use of smartphones and tablets, coupled with healthcare apps, is expected to propel the growth of the digital therapeutics market in the forecast period. Smartphones and tablet-based healthcare apps have numerous advantages over the lower rate of medication errors, facilitating preventive care, and more accurate staffing. For instance, according to the Groupe Speciale Mobile Association (GSMA) report, the number of smartphone users in the US reached 270 million in 2020. According to the Pew Research Center, a nonpartisan American think tank, the percentage of Americans who own a smartphone climbed from 81% in February 2019 to 85% in February 2021, which was just 35% a decade ago (in 2011).  Therefore, the increasing use of smartphones drives the growth of the digital therapeutics market. Technological innovation is an emerging trend gaining popularity in the digital therapeutics market. Major companies operating in the market are focused on developing technologically advanced solutions for digital therapeutics to strengthen their position. For instance, in 2020, Boehringer Ingelheim, a Germany-based pharmaceutical company, and Click Pharmaceuticals, a US-based prescription digital therapeutics business, have agreed to collaborate on the development and commercialization of a digital medication for schizophrenia patients worth more than $500 million. The treatment named CT-155 will be a mobile app developed on click's technology platform, according to the company. In April 2020, Novartis, a Switzerland-based pharmaceutical company, acquired Ambylotech for an undisclosed amount. This acquisition is expected to help Novartis to develop Amblyotech's novel digital technology to treat amblyopia or lazy eye through digital therapeutics. Amblyotech is a US-based digital therapeutics company. Major players in the digital therapeutics market are Omada Health Inc., WellDoc Inc., 2Morrow Inc., Livongo Health, Propeller Health, Pear Therapeutics, Canary Health Inc., Noom Health Inc., Mango Health Inc., Akili Interactive Labs, Better Therapeutics, Happify Health, Kaia Health, Medtronic PLC., Teladoc Health Inc., and Fitbit Health Solutions. North America was the largest region in the digital therapeutics market in 2022. The Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digital therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The digital therapeutics market consists of sales of products to treat a disease, manage a condition, and improve a health function. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digital therapeutics market is segmented - 1) By Product: Software, Devices 2) By Sales Channel: Business-To-Business (B2B), Business-To-Consumers (B2C) 3) By Application: Preventive Applications, Treatment Or Care-Related Applications